Skip To Main Content

Actualización normativa

En un entorno en constante cambio como el sistema de salud, es fundamental mantenerse al día con las nuevas normativas que afectan tanto a profesionales como a pacientes. En este espacio encontrará las leyes, decretos, resoluciones y acuerdos relacionados con el sistema de salud dinámico y en evolución.

También encontrará resúmenes, análisis y todo lo relacionado con la más reciente normatividad, para comprender el posible impacto de los cambios hacia los diferentes actores del sistema.

Ordenar por
Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Tolebrutinib Direct Effects on Myeloid Cells in PwMS

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Inside MS: Explore how BTK drives immune cell activation and CNS damage

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024